Focal Cerebral Arteriopathy Steroid Trial

NCT06040255 · Status: ENROLLING_BY_INVITATION · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-01-26

No results posted yet for this study

Summary

This comparative effectiveness trial (CET) in children with suspected focal cerebral arteriopathy (FCA) presenting with arterial ischemic stroke (AIS) or transient ischemic attack (TIA) will compare the use of early corticosteroid treatment (Arm A) versus delayed/no corticosteroid treatment (Arm B). Delayed corticosteroid treatment is given only for those demonstrating disease progression and is initiated as soon as the progression is detected (at any time after randomization). All participants will also receive standard of care therapy (aspirin and supportive care). Sites will randomize participants 1:1 to Arm A or B. Participants will be enrolled and randomized as soon as possible after their stroke/TIA up until 96 hours following the initial stroke/TIA event.

Conditions

  • Pediatric Stroke
  • Arteriopathy
  • Arterial Ischemic Stroke

Interventions

DRUG

methylprednisolone, prednisolone, prednisone

Any generic or brand-name methylprednisolone at the appropriate dose may be used. Likewise, any generic or brand-name prednisolone, or prednisone, at the appropriate dose may be used.

Sponsors & Collaborators

  • University of Cincinnati

    collaborator OTHER
  • Medical University of South Carolina

    collaborator OTHER
  • M.D. Anderson Cancer Center

    collaborator OTHER
  • University of Colorado, Denver

    collaborator OTHER
  • University of Iowa

    collaborator OTHER
  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH
  • American Heart Association

    collaborator OTHER
  • University of California, San Francisco

    lead OTHER

Principal Investigators

  • Heather J Fullerton, MD, MAS · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2029-07-31
Completion
2030-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06040255 on ClinicalTrials.gov